Sanofi &
Kiadis

have joined forces to expand and accelerate the potential benefits of novel cell-based therapies to treat cancer patients

Patient
Focus

Kiadis is focused on cell-based immunotherapy products for the treatment of life threatening diseases.

Novel Cell
Therapies

Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor.

K-NK
Pipeline

Kiadis has a pipeline of NK-cell based medicines in development to treat blood cancers, solid tumors, and infectious diseases.

For Investors

Sanofi Offers to Acquire Kiadis: Transaction Documents

Press release

Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer

29 Apr 2021

Investor Relations

Sanofi Investor Relations

Our uncompromising approach to serve patients, their families and care givers aims to minimize harm and maximize help – delivering personalized treatments for every single patient to offer hope, reduce suffering and provide new life.

Research focus

Kiadis is focused on developing new cancer immunotherapeutics as well as novel adjunctive treatments for patients undergoing hematopoietic stem cell transplants.

Careers

Join our Team

Employee Testimonials

 

“I find it very exciting to be working on topics that can at times be controversial and also high risk. It allows us to be pioneers in the field and make a massive impact on research and medicine.” — Rana Nikzad, Senior Scientist, NK Cell Program

Pipeline

kiadis pipeline image